Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A joint trial of the Australasian Leukaemia and Lymphoma Group (ALLG) and the French CLL branch of the French Innovative Leukemia Organization (FILO) evaluating role of Lenalidomide consolidation in patients with Chronic Lymphocytic Leukemia following initial fludarabine, cyclophosphamide and rituximab (FCR) Chemotherapy

Next Previous
Trial Profile

A joint trial of the Australasian Leukaemia and Lymphoma Group (ALLG) and the French CLL branch of the French Innovative Leukemia Organization (FILO) evaluating role of Lenalidomide consolidation in patients with Chronic Lymphocytic Leukemia following initial fludarabine, cyclophosphamide and rituximab (FCR) Chemotherapy

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CLL6 RESIDUUM

    • Most Recent Events

    • 12 Dec 2023 Status changed from active, no longer recruiting to discontinued because of an acute lymphoblastic leukemia (ALL) warning (3 of 56 patients [5.4%]) in the CLLM1 trial .
    • 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 15 Jun 2023 Results from an ancillary study assessing the health-related quality of life from French patients in this study, presented at the 28th Congress of the European Haematology Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top